Amgen Inc

₽12,500.00₽0.00 (0%)

Estimate

P/E

0.4

EPS

1,120.372

Beta

0.026

Growth

Revenue, YoY

10.38%

Net income, YoY

66.91%

FCF, YoY

83.74%

Forecast

P/E (FWD)

19.5

EPS (FWD)

24.498

Dividends

Dividend yield

6.6%

Annual payout

$10.08

Next ex. div date

November 20, 26

Payout

66.45%

Div.growth, 5y

7.44%

Dividend growth streak

14 y

Div.rating

About the company

Ticker

AMGN-RM

ISIN

US0311621009

Country

United States of America

Sector (GICS)

Healthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Frequently asked questions

What sector does Amgen Inc (AMGN-RM) operate in?

Amgen Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is Amgen Inc (AMGN-RM) current stock price?

As of the latest data, Amgen Inc stock price is RUB 12,500.00, with a previous close of RUB 12,500.00.

What is Amgen Inc (AMGN-RM) current market capitalization?

Amgen Inc market cap is approximately 258.68 billion.

What is Amgen Inc (AMGN-RM) Earnings Per Share (EPS)?

The trailing EPS is RUB 1,120.37, and the forward EPS is RUB 24.50.

What is Amgen Inc (AMGN-RM) Price-to-Earnings (P/E) ratio?

Amgen Inc current P/E ratio is 0.43, with a forward P/E of 19.53.

What is Amgen Inc (AMGN-RM) EBITDA?

Amgen Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 358.32 billion.

Does Amgen Inc (AMGN-RM) pay dividends?

Yes. Amgen Inc pays quarterly dividends with an annualized yield of 6.6% and an estimated annual payout of RUB 10.08 per share.

When is the next ex-dividend date for Amgen Inc (AMGN-RM)?

The next ex-dividend date is scheduled for November 20, 2026.

How did Amgen Inc (AMGN-RM) perform in its most recent earnings report?

In the last report (September 30, 2026), Amgen Inc posted an EPS surprise of 12.32% and a revenue surprise of 8,299.5%.

What is Amgen Inc (AMGN-RM) beta (volatility) score?

Amgen Inc has a beta of 0.026, indicating lower volatility than the overall market.